Genetics of Dilated Cardiomyopathy: Clinical Implications
Authors, Journal, Affiliations, Type, DOI
- Authors: A. Paldino and G. De Angelis (equal first authors); M. Merlo; M. Gigli; M. Dal Ferro; G. M. Severini; L. Mestroni; G. Sinagra (senior author)
- Affiliations: Cardiovascular Department, Azienda Sanitaria Universitaria Integrata and University of Trieste (ASUITs), Trieste, Italy; Medical Genetics, Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy; Cardiovascular Institute and Adult Medical Genetics Program, University of Colorado Anschutz Medical Campus, Aurora, USA
- Journal: Current Cardiology Reports 2018;20(10):83 (published online 13 August 2018)
- Type: Narrative review, Myocardial Disease section
- DOI: 10.1007/s11886-018-1030-7
Overview
A 2018 narrative review of the genetic architecture of dilated cardiomyopathy, written when next-generation sequencing had pushed the gene list past 50 and a pathogenic variant could be found in almost 40% of familial cases. It covers the diagnostic yield and gene frequencies, the overlap between DCM and hypertrophic, restrictive and arrhythmogenic phenotypes, practical rules for testing probands and screening relatives, and a gene-by-gene account of genotype–phenotype correlation. Its central clinical claim is that LMNA was then the only DCM gene with a guideline-level management consequence — an ICD indication — while FLNC, TTN, DSP and DES carried recognisable but not yet guideline-actionable phenotypes. The review is useful now as a baseline against which the 2022–2026 guidelines and ClinGen curation can be read, not as current management guidance.
Keywords
Dilated cardiomyopathy; next-generation sequencing; genotype–phenotype correlation; lamin A/C; filamin C; precision medicine
Key Takeaways
Next-generation sequencing and gene diversity
- More than 50 genes have been associated with DCM; a causative variant is identified in approximately 40% of familial DCM, and sporadic forms frequently have a genetic background that family history alone misses because of incomplete penetrance and variable age of onset.
- TTN truncating variants are the commonest cause: 19–25% of familial and 11–18% of sporadic DCM, but also present in 2–3% of the healthy population, so not every TTN truncating variant is pathogenic.
- Sarcomeric genes MYH7, TNNT2 and TPM1 each account for roughly 5–10%; MYBPC3 mutations occur in DCM but are more typical of HCM.
- Cytoskeletal genes account for about 11% of DCM, led by FLNC (4% of DCM, 3% of arrhythmogenic DCM); DES accounts for 1–2% and dystrophin causes X-linked disease.
- LMNA is found in up to 8% of DCM patients and carries the most consequential management implications.
DCM as a multifaceted disease
- Three features shape interpretation: an extremely heterogeneous genetic background, overlapping phenotypes with HCM, RCM, ARVC and channelopathies, and a weaker association with any single monogenic variant than in HCM or ARVC.
- The same TNNT2 variant can produce DCM, HCM or RCM within one family; overlap should always be considered because it changes management.
- About 13% of patients carry at least two mutations, and compound mutations have been associated with worse prognosis; two or more variants of uncertain significance in one proband may jointly be disease-causing.
- Environmental modifiers — low-grade inflammation, alcohol, anthracyclines, peripartum state, tachycardia and sustained exercise — can unmask a predisposing genotype. Alcohol-induced and genetic DCM show a similar prevalence of DCM-causing genes.
Genetic testing in probands
- Testing is not required to make the diagnosis in typical DCM; it is most useful when the result changes management.
- Red flags that favour testing: conduction disease (AV block, intraventricular delay), major ventricular arrhythmias, family history of sudden cardiac death, skeletal myopathy with raised CK, posterolateral pseudo-necrosis on ECG, and posterolateral akinesia on echocardiography.
- Testing is recommended for familial DCM, and can be useful in apparently sporadic DCM once ischaemic, hypertensive, myocarditic, toxic and tachycardic causes are excluded.
- Borderline phenotypes — left ventricular non-compaction, left-dominant arrhythmogenic cardiomyopathy — are a specific use case where genotype can redirect the diagnosis.
Implications for relatives
- Cascade genetic screening follows identification of the index variant; autosomal dominant inheritance gives each first-degree relative a 50% probability of carrying it.
- First-degree relatives should be tested from age 10–12 years, with earlier testing considered in laminopathies; Sanger sequencing of the index variant is sufficient rather than a full panel.
- Asymptomatic carriers need lifelong surveillance: history, examination, ECG and echocardiography, with Holter and exercise testing as indicated; annually between 10 and 20 years, then every 1–3 years until the fifth or sixth decade to catch late-onset disease.
- Left ventricular enlargement without systolic dysfunction in a carrier signals higher probability of overt disease; reduced global longitudinal strain is the most promising early marker.
- Medical therapy is not started in genotype-positive, phenotype-negative relatives except in selected LMNA carriers; carriers should be counselled about transmission and about pregnancy as a potential unmasking trigger.
- Limitations: incomplete penetrance and variable onset make timing unpredictable; variant interpretation is increasingly dominated by VUS; and environmental or polygenic modifiers cannot be excluded in non-carriers.
Genotype–phenotype correlations
LMNA (lamin A/C)
- The strongest gene–phenotype association and the only one named in guidelines at the time; up to 8% of DCM.
- Early-onset (30s–40s) conduction disease, atrial fibrillation, ventricular arrhythmia and SCD, which can occur before systolic dysfunction; penetrance essentially complete by age 70.
- Non-missense variants (insertion, deletion, truncation, splicing) carry higher ventricular arrhythmia and SCD risk than missense variants.
- High event rates: mortality 12% at 4 years and up to 30% at 12 years, with frequent transplantation by age 45.
- Only gene with a guideline ICD indication: Class IIa, level B, in the presence of NSVT, LVEF <45% at first evaluation, male sex and non-missense variant; competitive sport is restricted at any age and an atrial lead should be considered when an ICD is implanted.
FLNC (filamin C)
- Truncating variants cause a left-dominant arrhythmogenic DCM with inferolateral subepicardial-to-transmural fibrosis and a high predisposition to malignant ventricular arrhythmia and SCD.
- A small cohort reported 15–20% malignant ventricular arrhythmia/SCD and 6% mortality over a median 5-year follow-up; fewer than 5% developed biventricular dilatation.
- Overlaps left-dominant arrhythmogenic cardiomyopathy; reverse remodelling is less frequent than in TTN disease.
DSP and other desmosomal genes
- Frameshift and nonsense DSP variants impair intercellular junctions and can produce predominant LV fibrosis and dysfunction with a high arrhythmic phenotype, with or without RV involvement.
- Desmosomal, LMNA and FLNC variants together account for most of the emerging "arrhythmogenic cardiomyopathy" overlap between DCM and ARVC.
TTN (titin)
- Truncating variants cause DCM with incomplete penetrance and mostly mild phenotypes; missense variants are generally benign.
- An arrhythmogenic DCM phenotype occurs, particularly with additional environmental factors; explanted tissue shows mitochondrial dysfunction, interstitial fibrosis and reduced hypertrophy.
- Left ventricular reverse remodelling rate ≥50%; an effect on death or transplantation has not been demonstrated.
DES (desmin)
- Causes 1–2% of DCM and a spectrum of skeletal and cardiac myopathy; cardiac involvement frequently includes conduction-system disease and ventricular arrhythmia, with probable LV fibrosis.
PLN (phospholamban)
- Arg9Cys causes severe early progressive heart failure and transplantation; Arg14del causes an early arrhythmogenic DCM with malignant ventricular arrhythmias.
- PLN mutations account for up to 15% of DCM in the Netherlands, reflecting the Arg14del founder effect.
SCN5A
- Missense variants (for example Arg222Gln) cause familial DCM with atrial and ventricular arrhythmia and AV block; the proposed mechanism is primary electrical dysfunction producing secondary dilatation.
RBM20
- Dominant mutations in 1–5% of familial DCM; a nuclear splicing regulator of TTN, MYH7 and TNNT2.
- High penetrance, pro-arrhythmic (particularly atrial fibrillation) and associated with rapidly progressive heart failure — described as behaving like LMNA and therefore a candidate for early identification and pre-symptomatic intervention.
Left ventricular reverse remodelling and prognostic scores
- DCM is dynamic: about 40% of patients achieve left ventricular reverse remodelling, spontaneously or with therapy, and this improves prognosis.
- Mutations in cytoskeleton/Z-disc genes — DES, FLNC, DMD, OBSL1, NEXN, MYPN, NEBL and LDB3 — were associated with a lower rate of reverse remodelling in a 152-patient cohort, independent of conventional clinical predictors.
- The authors argue for multiparametric prognostic scores combining genetics with biomarkers, ECG, Holter, echocardiography (including 3-D and speckle tracking), CMR (LGE, T1 mapping, feature tracking) and cardiopulmonary exercise testing.
Future perspectives
- The "final common pathway" concept: different genes converge on shared pathways, which could support pathway-specific therapy.
- ARRY-797, a p38-MAPK inhibitor, showed promising phase 2 results in LMNA-related DCM (NCT02057341) — a result later contradicted by the phase 3 REALM-DCM failure.
Limitations of the document
- Narrative review with no systematic search, meta-analysis or primary data; gene frequencies and outcome figures are drawn from small, often single-centre cohorts.
- Written in 2018: it predates the 2022 AHA/HF and ESC VA guidelines, the 2023 ESC cardiomyopathy guideline, ClinGen gene curation, DCM polygenic scores, and every current gene-specific risk calculator.
- Its management content is consequently historical — the LMNA ICD criteria and the "only gene with an indication" statement have been superseded.
- The genotype–phenotype table classifies associations as "actual", "evolving" or "conflicting" by author judgement rather than formal evidence grading.
- The reverse-remodelling conclusion rests on a single 152-patient cohort.
- ARRY-797 is presented as a promising LMNA therapy; the phase 3 REALM-DCM trial later found no benefit.
- No health-economic analysis, no paediatric or adult-congenital focus, and limited ancestry diversity in the cited cohorts.
Key Concepts Mentioned
- concepts/Genetic-Testing-in-Cardiomyopathy
- concepts/Cascade-Family-Screening
- concepts/Phenotypic-Approach-to-Cardiomyopathy
- concepts/VA-Risk-Stratification-DCM
- concepts/Arrhythmogenic-Cardiomyopathy
- concepts/Sudden-Cardiac-Death
Key Entities Mentioned
- entities/DCM
- entities/LMNA
- entities/FLNC
- entities/DSP
- entities/TTN
- entities/DES
- entities/PLN
- entities/SCN5A
- entities/RBM20
- entities/ALVC
- entities/ARVC
Wiki Pages Updated
- wiki/sources/genetics-dcm-ccreports-2018.md — created
- wiki/entities/RBM20.md — created
- wiki/entities/DCM.md — updated
- wiki/entities/LMNA.md — updated
- wiki/entities/FLNC.md — updated
- wiki/entities/TTN.md — updated
- wiki/entities/PLN.md — updated
- wiki/sourceindex.md — updated
- wiki/wikiindex.md — updated
- Genetics-index.md — updated